Loading...
RWD Case Studies2019-07-30T10:11:52+01:00

Former Commissioner says FDA has money and mandate to accelerate use of RWE in drug approval process

Earlier this month, former FDA Commissioner, Scott Gottlieb, spoke about real-world evidence (RWE) at the Patient-Centered Oncology Care meeting, in Philadelphia, Pennsylvania, saying that the FDA has the money and the mandate from Congress to accelerate the use of RWE in the drug approval process.

RWE is defined as “data regarding the usage, or the potential benefits or risks, of a drug derived from sources other than […]

Using WEP Clinical’s data collection platform to capture data from EAP patients

Challenge

A biopharma company developing a new drug for a rare form of cancer partnered with WEP Clinical to run an Expanded Access Program (EAP). Because the company’s drug is being developed to treat a rare condition, the clinical trial population is small. As such, the company wanted to be able to collect additional data from EAP patients to better understand patient’s quality of life and to gain additional insight on […]

WEP Clinical’s data collection platform allows sponsor to collect retrospective data from study-sites

Challenge

A rare disease company developing a new drug for a lysosomal storage disorder partnered with WEP Clinical to run an Expanded Access Program (EAP). The drug was already being provided under various investigator-sponsored EAPs. When this company opened their blinded clinical trial, additional EAP requests were being received and the company needed a trusted partner to manage the EAP requests. This program served many purposes: 1) transition existing compassionate use […]

NEED MORE INFORMATION?

CONTACT US